0001209191-19-025789.txt : 20190424
0001209191-19-025789.hdr.sgml : 20190424
20190424180419
ACCESSION NUMBER: 0001209191-19-025789
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190422
FILED AS OF DATE: 20190424
DATE AS OF CHANGE: 20190424
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: George Simeon
CENTRAL INDEX KEY: 0001595117
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38871
FILM NUMBER: 19764829
MAIL ADDRESS:
STREET 1: 161 WASHINGTON STREET
STREET 2: SUITE 500
CITY: CONSHOHOCKEN
STATE: PA
ZIP: 19428
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Turning Point Therapeutics, Inc.
CENTRAL INDEX KEY: 0001595893
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463826166
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 225
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-926-5251
MAIL ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 225
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: TP Therapeutics, Inc.
DATE OF NAME CHANGE: 20181018
FORMER COMPANY:
FORMER CONFORMED NAME: TP Therapeutics, INC
DATE OF NAME CHANGE: 20140106
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-04-22
0
0001595893
Turning Point Therapeutics, Inc.
TPTX
0001595117
George Simeon
C/O S.R.ONE, LIMITED
161 WASHINGTON STREET, SUITE 500
CONSHOHOCKEN
PA
19428
1
0
0
0
Common Stock
2019-04-22
4
C
0
1120730
A
1120730
I
By S.R.One, Limited
Common Stock
2019-04-22
4
C
0
546820
A
1667550
I
By S.R.One, Limited
Common Stock
2019-04-22
4
P
0
325000
18.00
A
1992550
I
By S.R.One, Limited
Stock Option (right to buy)
27.06
2019-04-22
4
A
0
15000
0.00
A
2029-04-21
Common Stock
15000
15000
D
Series C Preferred Stock
2019-04-22
4
C
0
4314809
0.00
D
Common Stock
1120730
0
I
By S.R. One, Limited
Series D Preferred Stock
2019-04-22
4
C
0
2105259
0.00
D
Common Stock
546820
0
I
By S.R.One, Limited
Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date.
S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein. Simeon J. George holds the title of Vice President at S.R. One, Limited and is an employee of GlaxoSmithKline LLC, a wholly-owned subsidiary of GlaxoSmithKline plc. Mr. George disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.
The shares were purchased at the Issuer's initial public offering.
The option will become fully vested on the date of the Issuer's 2020 annual meeting of stockholders.
As a Vice President of S.R. One, Limited and an employee of GlaxoSmithKline LLC, Simeon George is obligated to transfer any shares issued under the stock option to S.R One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc.
/s/ Brian Baker, Attorney-in-Fact
2019-04-24